TARRYTOWN, N.Y., Oct. 11, 2021 /PRNewswire/ -- Regeneron
Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it
will report its third quarter 2021 financial and operating results
on Thursday, November 4, 2021, before
the U.S. financial markets open. The Company will host a
conference call and simultaneous webcast at 8:30 AM Eastern Time that day.
Conference Call Information
Participants may access
the conference call live via webcast on the 'Investors and Media'
page of Regeneron's website at
https://investor.regeneron.com/events-and-presentations. To
participate via telephone, please register in advance at this link.
Upon registration, all telephone participants will receive a
confirmation email detailing how to join the conference call,
including the dial-in number along with a unique passcode and
registrant ID that can be used to access the call. A replay
of the conference call and webcast will be archived on the
Company's website for at least 30 days.
About Regeneron
Regeneron (NASDAQ: REGN) is a
leading biotechnology company that invents life-transforming
medicines for people with serious diseases. Founded and led for
over 30 years by physician-scientists, our unique ability to
repeatedly and consistently translate science into medicine has led
to nine FDA-approved treatments and numerous product candidates in
development, almost all of which were homegrown in our
laboratories. Our medicines and pipeline are designed to help
patients with eye diseases, allergic and inflammatory diseases,
cancer, cardiovascular and metabolic diseases, pain, hematologic
conditions, infectious diseases and rare diseases.
Regeneron is accelerating and improving the traditional drug
development process through our proprietary
VelociSuite® technologies, such as
VelocImmune®, which uses unique genetically
humanized mice to produce optimized fully human antibodies and
bispecific antibodies, and through ambitious research initiatives
such as the Regeneron Genetics Center, which is conducting one of
the largest genetics sequencing efforts in the world.
For additional information about the company, please visit
www.regeneron.com or follow @Regeneron on Twitter.
Contact Information:
Investor Relations
Mark Hudson
914.847.3482
mark.hudson@regeneron.com
Media
Alexandra Bowie
914.847.3407
alexandra.bowie@regeneron.com
View original
content:https://www.prnewswire.com/news-releases/regeneron-to-report-third-quarter-2021-financial-and-operating-results-and-host-conference-call-and-webcast-on-november-4-2021-301397234.html
SOURCE Regeneron Pharmaceuticals, Inc.